Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
ACADEMIA
Reproductive Medicine Society Issues Fertility Treatment Guidelines, Prods Careful Design for Health Coverage
As the government aims to introduce health coverage for fertility treatments next April, the Japan Society for Reproductive Medicine (JSRM) issued much-awaited guidelines on June 23 that serve as a springboard for discussions on designing the system. Recommending not only…
To read the full story
Related Article
- Chuikyo Backs MHLW Proposal on Fertility Treatment Coverage
December 16, 2021
- Chuikyo Calls for Smooth Transition to Fertility Treatment Coverage from Current Subsidy System
November 18, 2021
- Results of Guidelines-Related Studies Can Be Used in Public Knowledge-Based Filings for Fertility Treatments: MHLW
August 6, 2021
- Japan to Discuss Approval of Individual Fertility Drugs after August
July 26, 2021
ACADEMIA
- Consortium on Pediatric Drug Development Up and Running from This Fiscal Year
November 25, 2024
- Private-Academia Collab Yields 8 Pediatric Drug Approvals in Japan
November 8, 2024
- Alzheimer’s-Related Guidelines Being Revised to Accommodate Kisunla, Rexulti
November 6, 2024
- Japan Crafting Registry of All Hemophilia Patients, Company Use Eyed Too
November 5, 2024
- Pricing Partially to Blame for Diabetes Drug Shortage: Society Chair
November 5, 2024
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…